英文别名GSK2636771; GSK-2636771; GSK 2636771; 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid; cc-414; CS-0747; 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid; QCR-187; 2-Methyl-1-[2-methyl-3-(trifluoromethyl)benzyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid; 2-Methyl-1-[[2-Methyl-3-(trifluoroMethyl)phenyl]Methyl]-6-(4-Morpholinyl)-1H-benziMidazole-4-carboxylic acid; GSK2636771/GSK-2636771; 2-Methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid; 2-Methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-morpholino-benzimidazole-4-carboxylic acid; 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(morpholin-4-yl)-1H-1,3-benzodiazole-4-carboxylic acid; 2-methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-(morpholin-4-yl)-1H-1,3-benzodiazole-4-carboxylic acid; PI3K-beta Inhibitor GSK2636771